MedTrace Logo

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

NCT02780115 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2020-12-22

Study results available
· View outcomes & findings →

Summary

This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).

Conditions

Interventions

DRUG

AGN-199201 ophthalmic solution

1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

DRUG

AGN-190584 ophthalmic solution

1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.

DRUG

AGN-199201 Vehicle

Vehicle to AGN-199201

DRUG

AGN-190584 Vehicle

Vehicle to AGN-190584

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Haixia Liu · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-26
Primary Completion
2017-10-31
Completion
2017-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02780115 on ClinicalTrials.gov